Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study

Introduction: Information regarding chronic urticaria patients in the real-world setting is scarce. This analysis reports the two-year results of Portuguese patients included in the AWARE study.Material and Methods: Non-interventional cohort study. Adult patients with a diagnosis of chronic urticaria with symptoms for at least two months, refractory to H1-antihistamines, consulting one of the 10 participating urticaria centers throughout Portugal, from the 31st October 2014 to 31st July 2015, have been included in the study. Clinical parameters, medicines taken for urticaria symptom relief, weekly urticaria activity score, and dermatology quality of life index have been collected throughout the two years of the study.Results: Seventy-six patients were enrolled in the study. Results showed that the proportion of patients with omalizumab therapy almost duplicated after two years of the AWARE study, which was accompanied by the decrease of medical resources use and absenteeism. Moreover, urticaria severity and impact on quality of life both decreased after one year and continued to decrease at two years, although decreased severity was significant at both time points and quality of life was only significant at two years. At the end of two years, 79.0% of patients had their disease controlled compared to 29.3% at baseline (p < 0.001).Discussion: At the end of the AWARE study a significant proportion of patients had their disease controlled allowing for decreased use of medical resources.Conclusion: Chronic urticaria still has a significant impact on quality of life and therefore there is opportunity for further therapy optimization.

Download Full-text

Chronic Urticaria in the Real-Life Clinical Practice Setting in Portugal: Baseline Results from the Non-Interventional Multicentre AWARE Study

Acta Médica Portuguesa ◽

10.20344/amp.9496 ◽

2019 ◽

Vol 32 (2) ◽

pp. 133 ◽

Cited By ~ 4

Author(s):

Ana Célia Costa ◽

Isabel Rosmaninho ◽

Arminda Guilherme ◽

José Ferreira ◽

Joana Antunes ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Urticaria ◽

Real World ◽

Life Index ◽

The Real ◽

Real World Setting ◽

H1 Antihistamines ◽

Quality Of Life Index ◽

Urticaria Activity Score

Introduction: There is a paucity of information regarding chronic urticaria patients’ care in a real-world setting. The objective of this study was to report and evaluate the baseline characteristics of Portuguese chronic urticaria patients refractory to H1-antihistamines included in the AWARE study. Material and Methods: This is a non-interventional cohort study. Adult patients with a diagnosis of chronic urticaria with symptoms for at least two months, refractory to H1-antihistamines, consulting one of the 10 participating urticaria centers throughout Portugal have been included in the study. Baseline sociodemographic data, medical history, clinical parameters, medication, weekly urticaria activity score, and dermatology quality of life index have been collected. Results: Seventy six patients were included, of which 76.3% were women. The majority of patients had a diagnosis of chronic spontaneous urticaria (88.2%) and 39.5% had angioedema. Around 91.0% of patients were medicated with non-sedative H1-antihistamines and 35.4% with a third line therapy. Median dermatology quality of life index was 5.0 and median weekly urticaria activity score was 13.0. Discussion: The baseline results suggest that patients with chronic urticaria refractory to H1-antihistamines are being under-treated in the real-world setting. Conclusion: The AWARE study demonstrates the real impact of chronic urticaria on Portuguese patients refractory to H1-antihistamines treatment, and 30% report a very large or extremely large deleterious effect on their quality of life. The follow-up of these patients will allow evaluating strategies aimed at optimizing disease control.

Download Full-text

The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations

International Journal of Dermatology ◽

10.1111/ijd.15006 ◽

2020 ◽

Vol 59 (8) ◽

pp. 893-901

Author(s):

Samah Tawil ◽

Carla Irani ◽

Riwa Kfoury ◽

Pascale Salameh ◽

Ilaria Baiardini ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Urticaria ◽

Activity Score ◽

Life Questionnaire ◽

Questionnaire Validation ◽

Quality Of Life Questionnaire ◽

Urticaria Activity Score

Download Full-text

A Real-Life Context on Adult Survivors’ Perceived Quality of Life, Spirituality, and Resiliency

Philippine Social Science Journal ◽

10.52006/main.v3i1.113 ◽

2020 ◽

Vol 3 (1) ◽

pp. 21-34

Author(s):

Rogen Ferdinand E. Alcantara

Keyword(s):

Quality Of Life ◽

Real Life ◽

Adult Survivors ◽

Well Being ◽

The Real ◽

Perceived Quality Of Life ◽

Life Context ◽

Spiritual Struggles

This study aims to determine the real-life context on quality of life, spirituality, and resiliency among natural disaster adult survivors in Negros Oriental and Bohol. The case study method was utilized to investigate the real-life experiences of seven (7) adult survivors, ages 20 and older, who joined in the Silliman University Continuing Calamity Response Program. The narratives revealed a commonality of opinions on their quality of life. General sentiment on the available resources may be present but was inadequate. However, despite their ominous view on the quality of life, the majority of the participants chose to move on. Moreover, most participants indicate experiencing spiritual struggles, but these struggles sustained them. Momentarily, the love and support from their family and the community have allowed them to strive and make life adjustments. With this, balanced and holistic recovery programs should be implemented to obtain optimal well-being, spiritual empowerment, and positive resiliency.

Download Full-text

Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2018.03.002 ◽

2018 ◽

Vol 17 (3) ◽

pp. e457-e470 ◽

Cited By ~ 8

Author(s):

Alessandro Pastorino ◽

Maria Di Bartolomeo ◽

Evaristo Maiello ◽

Vincenzo Iaffaioli ◽

Libero Ciuffreda ◽

...

Keyword(s):

Quality Of Life ◽

Real Life ◽

Italian Patient ◽

The Real ◽

Patient Cohort ◽

Life Data ◽

Real Life Setting

Download Full-text

Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.3_suppl.545 ◽

2014 ◽

Vol 32 (3_suppl) ◽

pp. 545-545 ◽

Cited By ~ 3

Author(s):

Roberto Bordonaro ◽

Alberto F. Sobrero ◽

Luca Frassineti ◽

Libero Ciuffreda ◽

Giuseppe Aprile ◽

...

Keyword(s):

Quality Of Life ◽

Interim Analysis ◽

Safety Data ◽

Real Life ◽

The United States ◽

Real Life Setting ◽

Safety Population ◽

Study Results ◽

Initial Starting

545 Background: The prespecified analysis of patients ≥65 years of age in the VELOUR study demonstrated a safety profile similar to that of ziv-aflibercept (Z) (known as aflibercept outside the United States) plus FOLFIRI in the overall VELOUR study. Results from VELOUR supported the initiation of the global Aflibercept Safety and Quality-of-Life (QoL) Program composed of two clinical studies (ASQoP [NCT01571284]; AFEQT [NCT01670721]) to capture QoL and safety data from a target population similar to that of VELOUR in a real-life setting. We report early safety data from this interim analysis for patients ≥65 y. Methods: ASQoP and AFEQT are single-arm, open-label trials evaluating safety and QoL of Z in mCRC patients previously treated with an oxaliplatin-containing regimen. Eligible patients received Z (4 mg/kg) q2wks on day 1 of each cycle followed by FOLFIRI until disease progression, unacceptable toxicity, death, or investigator/patient decision. Initial starting doses and subsequent dose modifications are at the treating physician’s discretion. The percentage of patients ≥65 y with grade (G) 3/4 adverse events (AEs) in the combined safety population of ASQoP and AFEQT are compared with that of the prespecified analysis in patients ≥65 y from VELOUR. Results: At data cut-off, the safety population comprised 116 patients with at least 1 completed cycle of treatment; 53 (45.7%) were ≥65 y. At least 1 G3/4 AE was experienced by 64.2% of patients vs 89.3% in VELOUR. Most reported G3/4 AEs were G3. There were no reports of G4 hypertension, diarrhea, stomatitis, or proteinuria. Conclusions: Thisinterim safety analysis from ASQoP and AFEQT in patients ≥65 y has identified no new safety signals. The early interim analysis provides additional safety data and suggests an acceptable toxicity profile in this real-life setting. Clinical trial information: NCT01571284. [Table: see text]

Download Full-text

A Specialized Therapeutic Approach to Chronic Urticaria Patient’s Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience

Journal of Investigational Allergology and Clinical Immunology ◽

10.18176/jiaci.0661 ◽

2020 ◽

Vol 32 (3) ◽

Author(s):

A Gimenez-Arnau ◽

J Bartra ◽

M Ferrer ◽

I Jauregui ◽

J Borbujo ◽

...

Keyword(s):

Quality Of Life ◽

Disease Activity ◽

Chronic Urticaria ◽

Life Quality ◽

Life Questionnaire ◽

H1 Antihistamines ◽

Third Line ◽

International Multicenter Study ◽

Urticaria Activity Score

Objective: AWARE study assesses disease activity, patient’s quality of life (QoL) and treatment patterns in chronic urticaria (CU) patient’s refractory to H1-antihistamines (H1-AH) in clinical practice during the first year of the study. Methods: Observational, prospective (24 months), international, multicenter study. Patients ≥18 years with H1-AH-refractory CU diagnosis (>2 months). At each visit, patients completed questionnaires to assess disease burden (Urticaria Control Test [UCT]), disease activity (7 day-Urticaria Activity Score [UAS7]), QoL (Dermatology Life Quality index [DLQI], Chronic Urticaria Quality of Life Questionnaire [CU-Q2oL], Angioedema Quality of Life [AE-QoL]). We present Spanish data. Results: 270 evaluable patients included (73.3% female, mean age [SD] 48.9 [14.7] years). At baseline, 89.3% were prescribed a CU treatment. After 1-year, first/second line treatments tended to decrease and third line to increase. 47.0% patients experienced angioedema at baseline, being 11.8% at 1-year. Mean (SD) AE-QoL went from 45.2 (28.7) to 24.0 (25.8). Mean (SD) UCT went from 7.0 (4.5) to 12.1 (4.1). According to UAS7, 38.2% patients reported absence of wheals and itch in the last 7 days at 1-year versus 8.3% at baseline. Mean (SD) DLQI went from 8.0 (7.4) to 2.8 (4.6). At 1-year visit, the percentage of patients reporting high/very high QoL impact went from 29.9% to 9.6%. Conclusions: Spanish H1-AH-refractory CU patients present a lack of symptomatology control with an important impact in their QoL. Continuous follow-up of chronic spontaneous urticaria patients and third line therapies have shown a tendency to reduce the burden of the disease and to improve patients’ QoL.

Download Full-text

Chronic Urticaria: Indian Context—Challenges and Treatment Options

Dermatology Research and Practice ◽

10.1155/2013/651737 ◽

2013 ◽

Vol 2013 ◽

pp. 1-8 ◽

Cited By ~ 3

Author(s):

Sujoy Khan ◽

Anirban Maitra ◽

Pravin Hissaria ◽

Sitesh Roy ◽

Mahesh Padukudru Anand ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Urticaria ◽

Treatment Options ◽

Significant Proportion ◽

Multidisciplinary Management ◽

Common Condition ◽

Indian Context ◽

Long Acting ◽

Pressure Urticaria

Urticaria is a common condition that occurs in both children and adults. Most cases have no specific allergic trigger and the aetiology of urticaria remains idiopathic and occasionally spontaneous in nature. Inappropriate advice such as avoidance of foods (milk, egg, prawn, and brinjal) is common place in certain sections of India mostly by nonspecialists that should not be routinely recommended. It is important to look for physical urticarias such as pressure urticaria in chronic cases, which may be present either alone or in combination with other causes. Autoimmune causes for chronic urticaria have been found to play an important role in a significant proportion of patients. Long-acting nonsedating antihistamines at higher than the standard doses is safe and effective. Quality of life is affected adversely in patients with chronic symptomatic urticaria and some may require multidisciplinary management.

Download Full-text